EXAMINE THIS REPORT ON TRASTUZUMAB MONITORING

In July 2024, the CHMP adopted a favourable opinion, recommending the granting of a marketing and advertising authorization to the medicinal product Tuznue, meant for that therapy of breast and gastric cancer.Information from a little stage II research support using trastuzumab in combination with pertuzumab and weekly paclitaxel within the adminis